Immunitybio, INC Form 4 insider transactions

ImmunityBio, Inc. Director Michael D. Blaszyk was granted 162,786 stock options with an exercise price of $2.84, vesting over approximately one year.

ImmunityBio, Inc. Director Linda Maxwell was granted 162,786 stock options with an exercise price of $2.84, vesting on the earlier of June 18, 2026, or the next annual meeting.

ImmunityBio, Inc. Director Wesley Clark was granted 162,786 stock options with an exercise price of $2.84, vesting by June 2026, as part of a pre-arranged compensation plan.

Regan J. Lauer, Chief Accounting Officer of ImmunityBio, Inc., reports the vesting and subsequent disposal of shares to cover tax obligations.

Patrick Soon-Shiong, a director and significant shareholder of ImmunityBio, exercised restricted stock units and reported changes in beneficial ownership, maintaining a substantial stake in the company through various entities.

David Sachs, CFO of ImmunityBio, reports the vesting of restricted stock units (RSUs) and subsequent disposition of shares to cover tax obligations.

CEO Richard Adcock of ImmunityBio, Inc. reports the vesting of restricted stock units (RSUs) and subsequent stock transactions.

Director Simon Barry J. Simon exercised stock options and disposed of shares of ImmunityBio, Inc. to cover tax obligations on February 22, 2025.

Patrick Soon-Shiong, Executive Chairman of ImmunityBio, reports the acquisition of stock options and restricted stock units in a recent SEC filing.

Regan J Lauer, Chief Accounting Officer of ImmunityBio, Inc., reports the acquisition of stock options and restricted stock units.

David C. Sachs, CFO of ImmunityBio, Inc., received stock options and restricted stock units on February 10, 2025, according to a Form 4 filing.

Richard Adcock, CEO and President of ImmunityBio, acquired stock options and restricted stock units (RSUs) on February 10, 2025, according to a recent SEC filing.

ImmunityBio director Barry J. Simon exercised stock options to acquire 110,020 shares of common stock at a price of $1.9984 per share.

CEO Richard Adcock reports the vesting of restricted stock units and subsequent stock transactions.

David Sachs, CFO of ImmunityBio, reports the vesting and disposal of restricted stock units and common stock on December 31, 2024.

ImmunityBio's Chief Accounting Officer, Regan J. Lauer, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Patrick Soon-Shiong and related entities converted over $230 million in debt into ImmunityBio stock and consolidated existing promissory notes.

John Owen Brennan, a director of ImmunityBio, Inc., acquired stock options for 77,633 shares on June 11, 2024.

Wesley Clark, a director at ImmunityBio, acquired stock options for 77,633 shares of common stock on June 11, 2024.

Cheryl Cohen, a director of ImmunityBio, Inc., acquired stock options for 77,633 shares of common stock on June 11, 2024.

Director Christobel Selecky reports acquisition of stock options in ImmunityBio, Inc. on June 11, 2024.

Michael D. Blaszyk, a director of ImmunityBio, Inc., acquired stock options for 77,633 shares on June 11, 2024.

Linda Maxwell, a Director at ImmunityBio, Inc., reports the acquisition of stock options exercisable for 77,633 shares of common stock.